Experiments on cell cultures showed the inhibitory effect of deuterium-depleted water, DDW, on the growth of tumor cells already in the early ‘90s. This antitumor effect has later been verified by several independent laboratories including Oncotech Inc. in California. The antitumor activity of DDW has also been investigated in vivo, in mice transplanted with human breast cancer; in a significant part of the mice the tumors showed regression or much slower growth.
Then, the effect of deuterium depletion was investigated in clinical tests on dogs and cats with spontaneous tumors, and the excellent antitumor effect of deuterium depletion has been verified also here. The treatment brought improvement in 70-80% of the pets, in numerous cases the disease could be reverted even from progressive state.
The results of human clinical studies confirmed the experiences of preclinical investigations. In the phase II study, 30% of the prostate tumor patients who consumed DDW showed substantial improvement, and the one-year survival rate was also significantly better among the DDW-consuming patients. Evaluation of retrospective studies on breast, lung and pancreas cancer patients likewise confirmed the advantages of DDW applied as supplementary treatment. Experiences showed also that the results (median survival, progression-free period etc.) obtained with conventional treatment could be increased severalfold by supportive application of DDW also in other kinds of tumors.
Mechanism of Action
Research of the last years clarified the role of deuterium as “onco-isotope” and the biochemical mechanism of deuterium depletion in the development of cancers and other chronic diseases. According to the latest results, properly functioning mitochondria (the cells’ energy centers) of healthy cells produce metabolic water with reduced deuterium content which has an extremely important role in maintaining normal cellular metabolism. Physiological deuterium depletion is accomplished via oxidation of fatty acids, because animal fats and vegetable oils contain by far less deuterium than e.g. hydrocarbons.
Strategic exchange of deuterium to hydrogen in drinking water and other foods, application of deuterium-depleted water fulfils, thanks to a “metabolic trick”, the same role, replacing in diseased cells what in normal cells mitochondria do by producing deuterium-depleted metabolic water. Deuterium-depleted water can restore normal cellular functions and metabolism even if the mitochondria do not work properly, and can hence be suitable for cancer prevention and curation, even in progressive cases.
Deuterium depletion influences also the activity of genes involved in tumorigenesis.
Molecular biological studies showed that subnormal deuterium level inhibited expression of the COX-2 gene in the HT-29 colon cancer cell line. The extent of COX-2 inhibition was correlated to D-level of water, resulting in stronger inhibition at lower D concentrations. In animal experiments it was investigated whether DDW had an influence on the expression of the oncogenes c-myc and Ha-ras, and of gene p53, in carcinogen-treated mice. In the group consuming DDW, expression of all three genes was significantly reduced in different organs (spleen, lungs, thymus, kidney, liver and lymph nodes) in 48 hours after the carcinogenic treatment. According to these results it is possible to influence the activity of genes involved in carcinogenesis by altering deuterium concentration.
Knowledge on the physiological role of deuterium and its application in the pharma industry opens up new ways of targeted therapy of primarily tumorous diseases by restoring normal cell functions via deuterium depletion.
On decreasing the concentration of deuterium below normal physiological level, the resulting depletion delayed the progression of several types of cancer in mice and prolonged the animals' survival. These findings were confirmed when dogs and cats with different spontaneous tumors were consuming DDW as drinking water. These experiments revealed that the tumors cannot tolerate the decrease of D concentration and after a relatively short time period (few weeks or months) they regress and then disappear.
The first deuterium depleted drug, Vetera-DDW-25® A.U.V, was registered for the supportive therapy of tumorous dogs and cats in 1999.
Among pets (mostly dogs and cats) the average tumor rate is 3-4%. VETERA-DDW-25® is applicable orally (by drinking), its main indication is pre- and post-treatment of surgical interventions, or single treatment in case of non-operable tumors. VETERA-DDW-25® is special in regard to its high efficacy in several different tumor types, which is coupled with lack of side effects and the scantiness of in-home chemotherapeutical treatments on the market.
Mammary tumors in dogs and cats showed a response rate over 70%; with more than 50% of the animals achieving complete recovery. Similar efficacy was observed in dogs and cats bearing rectal tumors. More than 70% of cats with lymphoid leucosis achieved complete response. Sarcomatoid tumors in dogs showed a short-term response or no response at all.
In order to increase the effectiveness of deuterium depletion, an injectable formulation of DDW was developed to ensure a rapid decrease in D concentration especially in certain types of cancer, such as ulcerative, extensive, relapsed, metastasizing tumors, malignant melanoma, and sarcomatoid tumors which were fairly resistant to per os DDW treatment.
Local treatment induced regression of tumors that were resistant to previous oral DDW administration and produced advantageous conditions for subsequent surgical interventions. Microscopic evaluations of the tumors verified that DDW injection induced disappearance of tumor cell infiltration, demarcation and consequent rejection of invasive tumors; but was harmless to the healthy tissues in the environment of the tumor. Simultaneous oral and local treatment was initiated in some animals to enhance therapeutic effectiveness and to prevent relapses. As a result of the combined treatment, dogs became tumor-free and asymptomatic. DDW injection alone or in combination with surgery offers an effective cancer treatment of aggressive tumors with poor prognosis.
The function of DDW in preventing cancer
The results of the basic research and long-term animal studies provided conclusive evidence on the cancer preventive effect of deuterium depletion. These results confirm, that decreased D concentration can intervene in the signal transduction pathways, and deuterium depletion induces increased apoptosis via inhibition of COX-2 gene expression and prostaglandin formation. In a long-term animal study, oral DDW administration inhibited the development of tumors in carcinogen-treated mice, proving the preventive effect.
DDW might be a harmless means of prevention, enabling us to interfere with the multi-level process of oncogenesis not only in its last phase but at a much earlier stage. According to our present knowledge, for preventive purpose it is sufficient to make a 2-3 months DDW cure once a year.
The effect of DDW on insulin resistance
The main clinical feature of metabolic syndrome (a complex metabolic disorder) is diminished insulin sensitivity. Insulin resistance is closely linked to high blood lipid and blood pressure levels which parameters are also the leading risk factors of cardiovascular diseases.
In a preclinical animal experiment, DDW enhanced the effect of insulin and improved glucose uptake of the cells in rats with artificial diabetes. Levels of blood glucose, fructosamine, and HbA1c were clearly and significantly lower in the animals that received DDW as drinking water and also insulin. These results suggested that, thanks to improvement of insulin sensitivity, DDW can be successfully applied in patients with metabolic syndrome.
In a human clinical study, 30 voluntary participants with impaired glucose tolerance received DDW treatment for 90 days. By following the physiological parameters related to insulin resistance, the possible effect of DDW on glucose metabolism was analyzed. Compared to the result of intravenous glucose tolerance test on day zero, 15 of the 30 participants had lower serum insulin level at the end of treatment (day 0: 18.0±13.3 μU/ml, day 90: 7.7±4.3 μU/ml, p=0.007).
At the end of the study, a close connection between lower insulin level and reduced glucose concentration in the serum could be verified. Insulin resistance was diminished in over 30% of the participants, as shown by the improved glucose uptake of the organism (8.6±2.5 mg/kg b.w./min vs. 6.9±2.4 mg/kg b.w./min). The simultaneous influence of DDW on serum insulin and glucose levels, and on insulin resistance, confirmed the close relationship of the typical physiological parameters of metabolic syndrome, and indicated a possible effect of D level in the organism on these.
Gábor Somlyai, Ildikó Somlyai, István Fórizs, György Czuppon, András Papp and Miklós Molnár (2021) Effect of Systemic Subnormal Deuterium Level on Metabolic Syndrome Related and other Blood Parameters in Humans: A Preliminary Study. Prime Archives in Molecular Sciences: 2nd Edition, 1-20.
Miklós Molnár, Katalin Horváth, Tamás Dankó, Ildikó Somlyai, Beáta Zs. Kovács, Gábor Somlyai (2021) Deuterium-depleted water stimulates GLUT4 translocation in the presence of insulin, which leads to decreased blood glucose concentration. Molecular and Cellular Biochemistry, 476:4507–4516.
Gábor Somlyai, Ildikó Somlyai, István Fórizs, György Czuppon, András Papp, Miklós Molnár (2020) Effect of Systemic Subnormal Deuterium Level on Metabolic Syndrome Related and other Blood Parameters in Humans: A Preliminary Study. Molecules, 25, 1376; doi:10.3390/molecules25061376
Somlyai, G., Somlyai, I., Fórizs, I., Czuppon, G., Papp, A., & Molnár, M. (2021) Preliminary Study on the Effect of Systemic Subnormal Deuterium Level on Metabolic Syndrome-Related and Other Blood Parameters in Humans. Current Advances in Chemistry and Biochemistry Vol. 4, 61–71.
Somlyai G., Molnár M., Somlyai I., Fórizs I., Czuppon Gy., Balog K., Abonyi O., Krempels K. (2014) A szervezet szubnormális deutériumszintjének kedvező élettani hatása a glükózintoleranciára, valamint a szérum HDL- és Na+-koncentrációra/Effect of subnormal level of deuterium on glucose tolerance, serum HDL- and Na+-concentration. Egészségtudomány/Health Science LVIII, 1, 104-123
M. Molnár, K. Horváth, T. Dankó, G. Somlyai (2010) Effect of deuterium oxide (D2O) content of drinking water on glucose metabolism on STZ-induced diabetic rats. Proceedings of the 7th International Conference Functional Foods in the Prevention and Management of Metabolic Syndrome 154-155
The effect of DDW on the performance of athletes
In a sports medicinal study, the effect of DDW on the performance of top athletes, and on the metabolic processes concomitant with physical load, first of all on glucose metabolism and acid-base balance, was investigated. Twelve members of the Hungarian men’s national rowing team took part in the study, 7 of them consumed 2 liters of low-deuterium drinking water (Preventa® 105) for 44 days while the other 5 (controls) had normal drinking water. Both groups underwent the same preparatory training.
On the 0th and 44th day, both had a multi-step load test. The rowers did 4x1500 m at increasing intensity, with 2 minutes break between the laps. Pulse rate was measured continually. From capillary blood samples taken in rest (R), after each load step (T1-T4) and in the 5th minute of restitution (R5), acid-base parameter (pH, pCO2, pO2, HCO3, BE), ions (Na+, K+, Cl-), as well as lactic acid and glucose level of the blood, and the anion gap were determined.
Measurement results confirmed that, following the deuterium level decrease due to DDW consumption, tissue oxygenation was improved, oxygen deficient state was less likely, mobilization and utilization of glucose was better, and the cells were more able to metabolically compensate the alterations caused by physical load. It is well known that, due to increased energy demand on load, there is first a decrease of blood glucose level. This was seen in the control group on the 0th and 44th day, and also in the treated group before DDW consumption. On the 44th day, however, no decrease of blood glucose was seen in the treated group. In that group, the difference after load levels T1 and T2 vs. measurements before treatment was significant.
Before treatment, glucose level decrease at T1 and T2 was 25-34%, but only 5-7% after DDW-consumption.
At T4, glucose level increased minimally (9%) vs. resting level in the first load test, but after application of DDW the increase was substantially higher, 46%. In absolute values, decrease was 1.9-2.6 mmol/L, and increase, at T4 only 0.4 mmol/L before DDW application. After 44 days of DDW-consumption, however, initial glucose level decrease was merely 0.4-0.5 mmol/L, and increase in the second half of the load test, 2.5 mmol/L. Following DDW-consumption, even the resting level of blood lactic acid was significantly lower than in the first load test, and this difference remained significant also in the measurements at T1 to T3.
The results indicate that the athletes could perform the different load levels with lower lactic acid concentrations after DDW consumption which suggests that under load the cells became anoxic less or only later, or their lactic acid elimination capacity was improved. The results were in unison with the subjective experiences of the athletes who reported better performance, faster regeneration, and more stamina on physical load after DDW-consumption. DDW is suitable for improving the performance of the organism in case of increased physical load.
Györe I., Somlyai G. (2005) Csökkentett deutérium tartalmú ivóvíz hatása a teljesítőképességre sportolóknál/ The effect of deuterium depleted drinking water on the performance of sportsmen. Sportorvosi Szemle/Hungarian Review of Sports Medicine 46/1:27-38.